A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Melanoma
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1. Has histologically or cytologically confirmed melanoma. 2. Has unresectable Stage Ill or Stage IV melanoma. 3. Has the presence of at least 1 measurable ·lesion by CT or MRI

You may not be eligible for this study if the following are true:

1. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy. 2. Has a known additional malignancy that is progressing or requires active treatment within the past 2 years. 3. Has known active CNS metastases and/or carcinomatous meningitis.